Bimekizumab – the first dual inhibitor of IL-17A and IL-17F – a novel treatment for psoriatic arthritis and axial spondyloarthritis
Authors:
M. Olejárová
Authors‘ workplace:
Revmatologický ústav, Revmatologická klinika 1. LF UK, Praha
Published in:
Čes. Revmatol., 32, 2024, No. 3, p. 100-106.
Category:
Úvodník
Overview
Bimekizumab – the first dual inhibitor of interleukin-17A (IL-17A) and interleukin-17F (IL-17F) – represents a new generation of biological therapies that brings significant progress in the management of spondyloarthritis (SpA). This monoclonal antibody specifically targets the pro-inflammatory cytokines IL-17A and IL-17F, which play a key role in the pathogenesis of SpA. This dual inhibition mechanism provides bimekizumab with a broader and more comprehensive effect on suppressing inflammatory processes compared to drugs that only target IL-17A.
In clinical studies, bimekizumab has demonstrated excellent efficacy in plaque psoriasis. In psoriatic arthritis (PsA), it led to rapid and effective suppression of joint inflammation in patients with active PsA naive to biological treatment (BE OPTIMAL study), as well as in patients with active PsA who had failed previous anti-TNF therapy (BE COMPLETE study). Bimekizumab has also proven effective in axial spondyloarthritis (axSpA) (BE MOBILE 1 study for non-radiographic axSpA and BE MOBILE 2 study for radiographic axSpA), where most patients with high or very high disease activity experienced a significant reduction in disease activity to low or no activity following treatment with bimekizumab.
The safety profile of bimekizumab is similar to that of other IL-17 inhibitors, with the most common adverse effects being upper respiratory infections, candidiasis, or mild injection site reactions; serious adverse effects are rare. The dual inhibition mechanism of bimekizumab offers a promising treatment alternative for patients who have not responded adequately to existing therapies or who have not tolerated them.
Keywords:
Psoriatic arthritis – IL-17 – axial spondyloarthritis – bimekizumab – IL-17 inhibition – dual IL-17 inhibition – psoriatic arthritis therapy – axial spondyloarthritis therapy
Sources
1. Taams LS, Steel, KJA, Srenathan U, et al. IL-17 in the immunopathogenesis of spondyloarthritis. Nat Rev Rheumatol. 2018; 14: 453–466.
2. Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018; 77(4): 523–532.
3. Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020; 11: 1894.
4. Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet 2021; 397(10273): 487–498.
5. Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet 2021; 397(10273): 475–486.
6. Thaçi D, Vender R, de Rie MA, et al. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. Br J Dermatol. 2023; 188(1): 22–31.
7. Strober B, Paul C, Blauvelt A, Thaçi D, et al. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. J Am Acad Dermatol. 2023; 89(3): 486–495.
8. McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet 2023; 401(10370): 25–37.
9. Merola JF, Landewé R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet 2023; 401(10370): 38–48.
10. Baraliakos X, Deodhar A, van der Heijde D, et al. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. Ann Rheum Dis. 2024; 83(2): 199–213.
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2024 Issue 3
Most read in this issue
- Principles of treating SLE according to the 2023 EULAR treatment recommendations update – commentary
- CAR-T cell therapy in systemic autoimmune rheumatic diseases
- Bimekizumab – the first dual inhibitor of IL-17A and IL-17F – a novel treatment for psoriatic arthritis and axial spondyloarthritis
- Editorial